Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH-mutant and 1p/19q-codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report

Affiliations

• ¹ Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
• ² Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology, Berlin, Germany.
• ³ Charité - Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
• ⁴ Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuropathology, Berlin, Germany.
• ⁵ Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurosurgery, Berlin, Germany.
• ⁶ Department of Pathology, University Medicine Greifswald, Greifswald, Germany.